NCT00343720View on ClinicalTrials.gov

Study of Alimta® (Pemetrexed) Plus VELCADE® (Bortezomib) or Alimta Alone or VELCADE Alone in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Prior Therapy

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

Not specified

Primary Completion Date

October 31, 2007

Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG

VELCADE

DRUG

Alimta

Trial Locations (1)

7100

Hopital de Jolimont, Haine-Saint-Paul

Sponsors
All Listed Sponsors
collaborator

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

INDUSTRY

lead

Millennium Pharmaceuticals, Inc.

INDUSTRY

NCT00343720 - Study of Alimta® (Pemetrexed) Plus VELCADE® (Bortezomib) or Alimta Alone or VELCADE Alone in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Prior Therapy | Biotech Hunter | Biotech Hunter